Your dashboard for the Wright-Tornier merger

Edit_Post_‹____OrthoStreams____daily_news__lists_and_commentary_—_WordPress

Oct 2, 2015 – Closing

2015? – Hart-Scott-Rodino Antitrust Approval – 2nd FTC request in February 2015

Nov 2014 – Wright and Tornier shareholder approval

Oct 27, 2014 – Merger announced

Wright-Tornier may have to sell off a Total Ankle to satisfy FTC for merger (OrthoStreams)
Wright Medical, Wrong Market by Stephen Simpson, CFA
Wright Medical And Tornier See A Desirable Partner Choose Another by Stephen Simpson, CFA
Wright Medical Continuing To Gain Share In A Growth Market by Stephen Simpson, CFA
BioMimetic receives approvable letter from FDA for bone graft therapeutic, lowers 2014 revenue guidance
Douglas W. House, SA News Ed…
- Wright Medical Group subsidiary BioMimetic receives an approvable letter from the FDA for the PMA for its Augment Bone Graft. The letter means that the agency deems the product safe and effective and is approvable subject to customary preapproval facilities inspections.
- Augment Bone Graft will be the first clinically proven protein therapeutic to enter the U.S. orthopedics market in over a decade. It offers an alternative to autograft in ankle and/or hindfoot fusion procedures. The market opportunity is ~$300M per year in the U.S.
- Separately, Q3 sales totaled $71.3M (+24%). Based on Q3 results, the company lowers its 2014 revenue guidance to $298M – 302M from $308M – 312M. Its earnings call will be November 5 at 3:30 pm CT/4:30 pm ET.